The St. Anna Children’s Cancer Research Institute together with the Medical University of Vienna’s Department of Transfusion Medicine will organise a workshop on „Applied Cell Therapy.“ The workshop will be held at the St. Anna...more

The ethics committee of Land Oberösterreich as well as the Austrian drug agency AGES PharmMed approved a substantial amendment to our GBM-Vax trial. This is intended to maintain the quality of final results and deliver first...more

Vienna, September 30, 2011. The Recruitment for the Activartis-Study is completed. 60 patients with aggressive brain cancer were included in the randomised, open-label, 2-arm, multi-centre phase II clinical study at eight...more

In order to further stress the innovative medicinal approach, the Trimed Biotech GmbH was renamed to Activartis Biotech GmbH. The Vienna-based company is in phase II of the clinical trials for a novel active cancer immune...more

The technological platform of the Trimed Biotech GmbH has now also been granted the patent: The method is protected by a series of patents describing the use of interleukin IL-12 expressing dentritic cells. The patents have...more

The Trivax therapeutic by Trimed is an autologous tumor vaccine which, as an active cancer immune therapy, mobilizes the patient‘s immune system so that it can destroy tumor tissue by itself. Similar approaches, also based on...more